Ironwood Pharmaceuticals (IRWD, Financial) experienced a notable stock price increase of 5.20%. The stock is currently trading at $4.56 per share with a trading volume of 1.01951 million shares, a turnover rate of 0.64%, and a price fluctuation of 7.27%.
Recent financial reports reveal that Ironwood Pharmaceuticals generated $91.59 million in revenue, with a net profit of $3.65 million, resulting in earnings per share of $0.02. The company's gross profit stood at $91.09 million, and it has a price-to-earnings ratio of -455.50.
Among the six institutions that rated the stock, 83% recommended buying, while 17% suggested holding, with no sell recommendations. Within the pharmaceutical industry, where Ironwood operates, the overall growth was 0.73%. Related stocks such as Scilex Holding Company, Sunshine Biopharma Inc, and Cbdmd, Inc. showed significant gains. Cbdmd, Inc., Therapeuticsmd, Inc., and Painreform Ltd. were notably active, with turnover rates of 84.86%, 60.06%, and 24.76%, respectively. Stocks with substantial price fluctuations included Therapeuticsmd, Inc., Cbdmd, Inc., and Sunshine Biopharma Inc., with amplitudes of 69.24%, 37.42%, and 18.21% respectively.
Ironwood Pharmaceuticals specializes in manufacturing both specialty and generic drugs. It focuses on advancing products in areas with unmet needs, including irritable bowel syndrome with constipation, chronic idiopathic constipation, uncontrolled gout-related hyperuricemia, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company aims to expand its research, development, manufacturing, and marketing capabilities through partnerships, commercial agreements, and acquisitions.
